Foresight Diagnostics

#ForesightDx is excited about our participation in the ESMO Congress 2024.    We will be presenting new Foresight CLARITY MRD data in breast cancer. Abstract, time and date to be announced.    We look forward to engaging with #oncology #biopharmaceutical and #research professionals to discuss how Foresight CLARITY™, our ultra-sensitive MRD assay, can enhance your clinical trials and research across both #lymphoma and #solidtumor indications.    Schedule a meeting with us here:    Email: BD@foresight-dx.com    Online: https://lnkd.in/eSisfcab    See you all there! #ESMO24 #BreastCancer #CancerDiagnostics #PrecisionMedicine #ClinicalTrials #LiquidBiopsy

#ForesightDx is excited about the upcoming #ASH24 conference in December. In anticipation, we look back on this great piece of evidence from #ASH23 where our co-founder, Dr. David Kurtz, summarizes one of the studies presented at the conference.   This study analyzed whether PhasED-Seq™ #MRD detection can predict early and sustained response to Ionca third-line treatment of Diffuse Large B-Cell Lymphoma (#DLBCL) #therapy in a study of the LOTUS-2 clinical trial.    Our ultra-sensitive liquid biopsy platform Foresight CLARITY™  is powered by our proprietary technology, PhasED-Seq™.    Watch the video here: https://t.ly/hkSa9   Read our recent research and publications here: https://t.ly/H-b3z #ClinicalTrial #PrecisionMedicine #LiquidBiopsy #ForesightCLARITY #PhasedSeq #Lymphoma #CancerDiagnostics

Allogene Therapeutics has presented a trial-in-progress poster for their 1L consolidation ALPHA3 clinical trial, which has the potential to redefine the future of CAR T and the treatment of #LBCL. The trial is using #ForesightDx's Foresight CLARITY™ IUO MRD platform to identify patients with LBCL who have minimal residual disease (#MRD) and are likely to relapse following standard first-line treatment. Click the link below to learn more about #ALPHA3. #LargeBCellLymphoma #Cancer #Diagnostics #LiquidBiopsy #PrecisionMedicine #Partnership #ForesightCLARITY #ClinicalTrials

We are pleased to share that our work was featured in DocWire News. Check out their summary of our poster "Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)" from #ASCO24: https://t.ly/4-bh2 The lead poster author Dr. James Isbell, MD, MSCI said, “Based on these results, we now have another new tool that can help clinicians determine the need for post-operative treatment.” See the full poster here: https://t.ly/5jnmc #ForesightDx is on a mission to improve the lives of cancer patients worldwide through #innovative #diagnostics. #LungCancer #NSCLC #MRD #ctDNA #ForesightCLARITY #PhasEDseq #LiquidBiopsy #PrecisionMedicine

In this video, Dr. Brian Sworder discusses the objective, methodology, and key results for one of the studies presented at the American Society of Hematology (#ASH) Annual Conference in 2023. The study shows the #utility of our proprietary technology, PhasED-Seq™ #MRD, vs. PET/CT to predict response following #curative intent induction #therapy in patients with diffuse large B-cell lymphoma (#DLBCL). #ForesightDx's ultra-sensitive liquid biopsy platform, Foresight CLARITY™ , is powered by PhasED-Seq™. Watch video here: https://t.ly/tyKgX Learn more about Foresight CLARITY here: https://t.ly/UnwGW #ForesightCLARITY #PhasEDseq #ctDNA #MRD #PrecisionMedicine #LiquidBiopsy

We are excited to share that three community cancer centers have been activated as the first sites for Allogene Therapeutics pivotal Phase 2 ALPHA3 trial evaluating cema-cel as part of 1L treatment in #LBCL. The trial is using #ForesightDx's Foresight CLARITY™ IUO MRD platform to identify patients with LBCL who have minimal residual disease (#MRD) and are likely to relapse following standard first-line treatment. Patient screening is now underway at Rocky Mountain Cancer Centers (RMCC) in Colorado, Astera Cancer Care (ACC) in New Jersey, and Norton Healthcare. Learn more: https://lnkd.in/gRCrNcE9 #AllogeneTherapeutics #ctDNA #LiquidBiopsy #Hematology #cancer #relapse #ForesightCLARITY

As June comes to an end, we would like to take time to recognize Cancer Survivor Month. The toll a #cancer diagnosis takes on individuals and their families is immeasurable. We #honor the #strength, #resilience and #courage of all cancer #survivors and their families this month, and always. #ForesightDx is committed to the fight against cancer with our ultra-sensitive minimal residual disease (#MRD) platform, Foresight CLARITY. We hope to continue to help clinicians detect #relapse more quickly so patients can get the treatment they need to beat cancer and #survive. #Together we can make a difference. #NationalCancerSurvivorMonth #PrecisionMedicine #LiquidBiopsy #ForesightCLARITY

#ForesightDx is on a mission to improve the lives of cancer patients worldwide through #innovative diagnostics. Identifying minimal residual disease from liquid biopsy following #cancer treatment is a promising method for earlier relapse detection. Minimal residual disease (#MRD) can be measured using circulating tumor DNA (#ctDNA) to determine whether a patient is likely to relapse. The ability to detect even the smallest traces of ctDNA after treatment could inform #therapeutic decisions aimed to control or cure cancer. Foresight CLARITY accurately detects MRD as early as end of treatment when ctDNA levels are at their lowest and often missed by conventional imaging and liquid biopsy methods. With Foresight CLARITY's unprecedented #sensitivity and superior prognostic #utility, get the data you need to see clearly and act decisively. Watch this video to learn more about Foresight CLARITY: https://t.ly/K_GOu Learn about our partnership with Allogene Therapeutics: https://t.ly/Zn0h8 Read our recent research and publications: https://lnkd.in/g7n_zHb6 #PrecisionMedicine #ForesightCLARITY #SeeClearlyActDecisively #CancerDiagnostics #LiquidBiopsy #lymphoma #solidtumor #oncology #hematology #clinicalresearch

#ForesightDx and Allogene Therapeutics are pleased to announce the initiation of Allogene's pivotal Phase 2 ALPHA3 trial investigating cemacabtagene ansegedleucel (cema-cel), an allogeneic CAR T product, as part of first-line treatment for patients with Large B-Cell Lymphoma (#LBCL) who are likely to relapse.    This is the first prospective trial to incorporate the Foresight CLARITY™ IUO MRD platform to identify patients with LBCL who have minimal residual disease (#MRD) and are likely to relapse following standard first-line treatment. Our Chief Operating and Compliance Officer Sandra Close said about the trial: “Following the FDA Advisory Committee’s recent recommendation to include MRD as an endpoint to accelerate clinical trials in multiple myeloma, the ALPHA3 trial is yet another step forward towards broader implementation of MRD detection in drug development and clinical decision making.”    We want to thank the teams across both Allogene Therapeutics and #ForesightDx for their incredible partnership and teamwork to achieve this milestone!    Read the full press release here: https://t.ly/Zn0h8   #ForesightDx #AllogeneTherapeutics #ForesightCLARITY #CARt #CancerResearch #ClinicalTrials #LBCL #Oncology #Hematology #MRD #ctDNA #PrecisionMedicine